Arovella Therapeutics Limited (ASX:ALA)

Market Cap	73.74M -22.5%
Revenue (ttm)	3.50M +1.7%
Net Income	-6.92M
EPS	-0.01
Shares Out	1.21B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,452
Open	0.0610
Previous Close	0.0610
Day's Range	0.0600 - 0.0610
52-Week Range	0.0580 - 0.1250
Beta	0.12
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 14, 2026

About Arovella Therapeutics

Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly know...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 27
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ALA

Financial Performance

In fiscal year 2026, Arovella Therapeutics's revenue was 3.50 million, an increase of 1.69% compared to the previous year's 3.44 million. Losses were -6.92 million, -7.89% less than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error